Ken Griffin Kazia Therapeutics LTD Call Options Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$0.2 - $0.46 $4,800 - $11,040
24,000 New
24,000 $5,000
Q4 2023

Feb 14, 2024
BUY
$0.39 - $0.99 $858 - $2,178
2,200 New
2,200 $0
Q3 2022

Nov 14, 2022
SELL
$1.1 - $4.19 $46,420 - $176,818
-42,200 Reduced 66.25%
21,500 $24,000

Others Institutions Holding KZIA

# of Institutions
16
Shares Held
1.73M
Call Options Held
24K
Put Options Held
0
View Full List

About KAZIA THERAPEUTICS LTD

KZIA Quotes by TradingView
  • Ticker KZIA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,111,300
  • Market Cap $96.1M
  • Description
  • Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various...
More about KZIA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email